Figure 2.

Rate ratios of serious hypoglycemia occurrence from the use of insulin secretagogues or metformin with versus without concomitant angiotensin-converting enzyme inhibitors

CI: confidence interval (based on a two-tailed test). *Precipitant-exposed time: days of concomitant use with a precipitant drug (angiotensin-converting enzyme inhibitor) during observation time since the initiation of the concomitant use. †Rate ratio: [(outcome occurrence rate during precipitant-exposed time)/(outcome occurrence rate during precipitant-unexposed time)]; confounder-adjusted.